Healthway Medical News

A growing collection.
Always here to read.

Explore every article we have published, from the latest edition to earlier discoveries. Search a subject, choose a topic or revisit a particular month.

Edition 28 Sep 202618 medical topicsOriginal sources linked

Cancer Treatment

6 articles · Newest source date first

observational (population registry analysis)
Cancer Treatment ·

WHO publishes first country-comparable childhood cancer survival estimates

WHO releases a global dataset with comparable five‑year survival estimates for childhood and adolescent lymphoid leukaemia across 194 countries, highlighting large survival gaps between regions and age groups.

Read article →
CHMP positive opinion
Cancer Treatment ·

Ensartinib gains a positive European opinion for ALK-positive lung cancer

The targeted medicine is intended for selected adults with advanced non-small cell lung cancer.

Read article →
Phase III topline result
Cancer Treatment ·

Enhertu meets Phase III PFS endpoint as first-line therapy for HER2-mutant advanced lung cancer

DESTINY-Lung04 met its primary progression-free survival endpoint versus platinum-pemetrexed chemotherapy plus pembrolizumab in previously untreated HER2-mutant advanced NSCLC.

Read article →
FDA accelerated approval
Cancer Treatment ·

New iberdomide combination receives accelerated approval for previously treated multiple myeloma

The FDA has added a new oral CELMoD-based combination after a large randomized trial showed substantially deeper MRD-negative responses.

Read article →
FDA accelerated approval
Cancer Treatment ·

Oncolytic viral therapy plus nivolumab approved for advanced melanoma after PD-1 treatment

A genetically modified virus is now part of an FDA-approved immunotherapy strategy for a defined group of advanced melanoma patients.

Read article →
Phase 1 · 324 patients
Cancer Treatment ·

First-in-class FcRH5×CD3 bispecific antibody shows activity in heavily pretreated myeloma

A fixed-duration cevostamab programme produced responses in a difficult late-line multiple myeloma population.

Read article →
Call WhatsApp Book